Company Description
Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects.
It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis.
The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology.
Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
| Country | MA |
| Founded | 2014 |
| IPO Date | May 9, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 66 |
| CEO | Craig R. Jalbert CIRA |
Contact Details
Address: 124 Washington Street, Suite 101 Foxboro, Massachusetts 02035 United States | |
| Phone | 617-577-0300 |
| Website | evelobio.com |
Stock Details
| Ticker Symbol | EVLO |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001694665 |
| CUSIP Number | 299734103 |
| ISIN Number | US2997342025 |
| Employer ID | 46-5594527 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Craig R. Jalbert CIRA | President, Secretary, Principal Executive, Financial and Accounting Officer and Director |
| Dr. Chun Zhang Ph.D. | Chief Technical Operations and Quality Officer |
| Dr. Mark Bodmer Ph.D. | Chief Scientific Officer and President of Research and Development |
| Jessica Cotrone | Vice President and Head of Communications |
| Leslie Wardwell-Scott Ph.D. | Vice President and Head of Corporate Development and Strategic Integration |
| Dr. Andrea Itano Ph.D. | Head of Research |
| Dr. Duncan McHale M.D., MBBS, Ph.D. | Chief Medical Officer |
| Douglas Maslin | Senior Director and Immunology Clinical Lead |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 8, 2024 | EFFECT | Notice of Effectiveness |
| Jan 26, 2024 | 15-12G | Securities registration termination |
| Jan 26, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jan 26, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jan 26, 2024 | POS AM | Post-Effective amendments for registration statement |
| Jan 26, 2024 | 8-K | Current Report |
| Dec 27, 2023 | 25-NSE | Filing |
| Dec 12, 2023 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Dec 12, 2023 | DEF 14A | Other definitive proxy statements |
| Dec 11, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |